NY-XYLEM
Manchester City stars Sergio Agüero, Phil Foden and Raheem Sterling all feature in an emotive new short film that aims to bring home the reality of the global water crisis to football fans across the world. Released on World Conservation Day, ‘The End of Football’ is the latest campaign by global water technology company, Xylem (NYSE:XYL) and Manchester City, to drive awareness of escalating water challenges among the Club’s huge fan base.
For many football fans the reality of living with extreme water scarcity is now just one generation away. The latest UN data estimates that almost 5 billion people globally could be living in areas of water scarcity by 20501 . The UK Environmental Protection Agency forecasts that, due to mounting pressures such as increased demand, aging infrastructure and climate change, parts of England could run out of water by 2045 – a warning echoed in a recent UK Public Accounts Committee report on the country’s water supplies2 .
The End of Football film , featuring multiple Manchester City footballers, aims to capture the imagination of football fans by depicting a world without water. Filmed in the Club’s iconic Etihad Stadium, the video highlights the detrimental impact that water complacency can have on society, including football, as it tracks one girl’s journey as a Manchester City fan.
Patrick Decker, Xylem President and Chief Executive Officer, said: “Water sits at the heart of human health and the sustainability of our planet. Through our partnership with City Football Group, we’re focused on mobilizing the global community to actively join us in safeguarding this precious resource. Together, we have a powerful opportunity to turn the tide on challenges like water scarcity and flooding and build a water-secure future.”
Pete Bradshaw, Head of Sustainability at Manchester City, said: “Xylem is doing incredible work to address water sustainability issues and Manchester City is proud to support them in this new campaign.”
Joseph Vesey, Senior Vice President and Chief Marketing Officer at Xylem, added: “Though the End of Football campaign was conceived and shot before the coronavirus pandemic brought a temporary halt to football, the message behind the campaign has never been more appropriate. With the support of the Club and its legions of fans, we have the power to elevate the conversation on water conservation and create a more sustainable future for all.”
Fans can learn more about water conservation through the Manchester City ‘Water Hero Playbook’ , which contains simple, everyday actions on saving water – along with advice from public officials and industry – to protect our future and the future of football.
As part of its multi-year partnership with Manchester City, Xylem has partnered with the Club to deliver clean water towers, WASH education, and sports and leadership training to communities around the world. In less than two years, the partnership has already directly provided access to clean water and WASH education to over 10,000 children across India, Thailand, China, Australia and the United States.
Global sports marketing agency SPORTFIVE and its creative agency partner Brave developed and produced the End of Football campaign. As Xylem’s retained agency, SPORTFIVE has been helping the global water technology company and Manchester City FC to raise awareness of water complacency since 2018.
About Xylem
Xylem (XYL) is a leading global water technology company committed to developing innovative technology solutions to the world’s water challenges. The Company’s products and services move, treat, analyze, monitor and return water to the environment in public utility, industrial, residential and commercial building services settings. Xylem also provides a leading portfolio of smart metering, network technologies and advanced infrastructure analytics solutions for water, electric and gas utilities. The Company’s more than 16,000 employees bring broad applications expertise with a strong focus on identifying comprehensive, sustainable solutions. Headquartered in Rye Brook, New York, with 2019 revenue of $5.25 billion, Xylem does business in more than 150 countries through a number of market-leading product brands. For more information, please visit us at www.xylem.com .
About Xylem Watermark
Xylem Watermark, the company’s corporate citizenship program, was initiated in 2008, with a focus on protecting and providing safe water resources for communities around the world and also educating people on water related issues. In 2016, Xylem Watermark launched a three-year program focusing on employee volunteerism globally to drive rapid growth in employee engagement in providing social value within our communities.
About Manchester City Football Club
Manchester City FC is an English Premier League club initially founded in 1880 as St Mark’s West Gorton. It officially became Manchester City FC in 1894 and has since then gone onto win the European Cup Winners’ Cup, six League Championship titles, including four Premier League titles (2012, 2014, 2018, 2019), and six FA Cups. Manchester City FC is one of nine clubs comprising the City Football Group and counts New York City FC and Melbourne City FC among its sister clubs.
Under manager Pep Guardiola, one of the most highly decorated managers in world football, the Club plays its domestic and UEFA Champions League home fixtures at the Etihad Stadium, a spectacular 55,000 seat arena that City have called home since 2003. Today, the Stadium sits on the wider Etihad Campus, which also encompasses the City Football Academy, a state-of-the-art performance training and youth development facility located in the heart of East Manchester. Featuring a 7,000 capacity Academy Stadium, the City Football Academy is also where Manchester City Women’s Football Club and the Elite Development Squad train on a daily basis and play their competitive home games.
For more information, please visit www.mancity.com
About SPORTFIVE
SPORTFIVE is a global partnership marketing agency fuelled by the expertise, experience and privileged access of a global leader in sports, entertainment, media and lifestyle.
We help brands engage with their audiences and fans through partnerships, as we believe that partnering with things that people truly care about is the best way for brands to remain relevant and impactful.
About Brave
Brave is an award-winning creative agency that de-risks commercial decision-making by being creatively courageous, strategically forensic, digitally progressive, data smart and behaviour driven. We make progressive ideas feel safe – through a belief that creativity and data have a complementary relationship. We pioneered the use of biometrics through the development of our proprietary ‘Bravery Index’ tool. This has helped us optimise our work ever since, by letting us emotionally test, qualify and validate our campaigns for a greater chance of enjoying commercial success.
In 2017 Brave was acquired by SPORTFIVE , which provides a global footprint and access to the world’s most sought-after rights holders, talent, OTT (streaming) platforms/broadcasters and brands. Brave have taken the stage at prestigious events all over the world including; Cannes Lions, Advertising Week, IAB Engage, Eurobest and Dubai Lynx. For more information, find us at Brave.co.uk.
__________________
1
https://www.wateraid.org/uk/media/un-warns-around-5-billion-people-could-face-water-shortages-by-2050-wateraid-response
2
https://www.nao.org.uk/press-release/water-supply-and-demand-management/
View source version on businesswire.com: https://www.businesswire.com/news/home/20200728005532/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Granted U.S. FDA Fast Track Designation for BGB-B2033 as Treatment for Hepatocellular Carcinoma18.12.2025 12:00:00 CET | Press release
BGB-B2033 is a bispecific antibody directed at GPC3 and 4-1BB; key targets in the most common liver cancerFDA Fast Track Designation reflects the potential of BGB-B2033 in an area of high unmet need BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted the Company Fast Track Designation for BGB-B2033, its GPC3x4-1BB bispecific antibody for the treatment of adult patients with hepatocellular carcinoma (HCC) with disease progression on or after prior systemic treatment. “The FDA awards Fast Track Designation to therapies that show potential to address an unmet medical need in serious or life-threatening conditions. The FDA’s decision reflects the encouraging profile of BGB-B2033 in advanced hepatocellular carcinoma, where patients continue to face limited treatment options,” said Julie Lepin, Senior Vice President and Chief Regulatory Affairs Officer at BeOne. BeOne is currentl
NHOA Energy Achieves Great Place To Work Certification in Italy, the United States and Australia18.12.2025 10:53:00 CET | Press release
NHOA Energy, global provider of utility-scale energy storage systems, announces that it has been certified Great Place To Work® in Italy, the United States, and Australia. The certification is based entirely on direct feedback from NHOA Energy employees, gathered through an independent and structured listening process. Great Place To Work® Certification™ assesses the quality of the employee experience across key dimensions such as credibility, respect, fairness, pride, and camaraderie. The results achieved by NHOA Energy reflect a corporate culture built on trust, inclusion, and the consistent commitment to valuing people within a dynamic and international environment. Employees highlighted particularly high levels of appreciation for the ethical and transparent behavior of leaders, the welcoming and inclusive approach toward new hires, and fair treatment across diversity, equity, and inclusion dimensions. A strong majority also expressed pride in working at NHOA Energy and reported a
Regnology Signs an Agreement to Acquire Moody’s Regulatory Reporting & ALM Solutions18.12.2025 10:00:00 CET | Press release
The deal further strengthens Regnology’s global position in Regulatory Reporting and significantly accelerates its expansion into new markets Regnology, a leading provider in regulatory, risk, tax, and finance reporting, as well as supervisory technology, today announced it has signed an exclusive agreement for the acquisition of Moody’s Regulatory Reporting & ALM Solutions business, inclusive of solutions for Basel III compliance, IFRS9 impairment accounting, large bank asset-liability management (ALM), Solvency II insurance reporting, and prudential and statistical regulatory reporting across more than 50 jurisdictions. By integrating Moody’s regulatory capital and liquidity capabilities with Regnology’s regulatory, risk, and finance offerings, the firm is creating a unified, scalable platform designed to meet the full spectrum of financial regulatory compliance and risk requirements. This combined strength positions Regnology as the partner of choice for financial institutions seeki
Reply Recognized as a Microsoft Azure Expert Managed Services Provider for the Sixth Consecutive Year18.12.2025 10:00:00 CET | Press release
Reply [EXM, STAR: REY] announced today it has been recognized once again as a Microsoft Azure Expert Managed Services Provider (MSP). The renewal reaffirms Reply’s proven expertise and consistent track record in delivering high-quality cloud solutions and services on the Microsoft Azure platform, powered by the deep technical expertise of its specialized companies – Cluster Reply, Solidsoft Reply and Valorem Reply. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218596617/en/ This recognition reflects the ongoing collaboration between Reply - through its companies Cluster Reply, Solidsoft Reply, and Valorem Reply - and Microsoft, supporting shared efforts to deliver value-driven services to enterprise customers. The Azure Expert MSP program is designed by Microsoft to identify and validate partners with proven capabilities in delivering end-to-end Azure services at scale. To qualify, partners must meet a strict set of requ
Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment18.12.2025 09:00:00 CET | Press release
Pivotal Phase 3 studies of once-daily oral zasocitinib met all primary and ranked secondary endpoints in patients with moderate-to-severe plaque psoriasis More than half of study participants treated with zasocitinib achieved clear or almost clear skin (PASI 90), and on average about 30 percent achieved completely clear skin (PASI 100) by week 16 Zasocitinib was generally well-tolerated with a safety profile consistent with previous clinical studies Takeda(TSE:4502/NYSE:TAK)today announced positive topline results for the two pivotal Phase 3randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO). The studies demonstrated superiority of zasocitinib compared to placebo for the co-primary endpoints, static Physician Global Assessment (sPGA) 0/1 and Psoriasis Area and Severity Index (PASI) 75, at wee
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom